SciELO - Scientific Electronic Library Online

 
vol.29 issue1Frequency of suicide attempts and attitudes toward suicidal behaviour among doctors and nurses in Lagos, NigeriaThe prevalence and clinical correlates of substance use disorders in patients with psychotic disorders from an Upper-Middle-Income Country author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • On index processCited by Google
  • On index processSimilars in Google

Share


South African Journal of Psychiatry

On-line version ISSN 2078-6786
Print version ISSN 1608-9685

Abstract

ORD, Katherine L.  and  MARAIS, Belinda. Clozapine use at a specialised psychiatric hospital in Johannesburg. S. Afr. j. psyc. [online]. 2023, vol.29, n.1, pp.1-9. ISSN 2078-6786.  http://dx.doi.org/10.4102/sajpsychiatry.v29i0.1999.

BACKGROUND: Clozapine is the gold standard medication for treatment-resistant psychosis, with robust evidence supporting its efficacy in multiple symptom domains. However, clozapine's side effect profile contributes to its underutilisation and discontinuation. AIM: This study aimed to explore the magnitude of clozapine use and describe factors that impact on its effective use among in-patients. SETTING: Tara Hospital, a specialised psychiatric hospital in Johannesburg. METHODS: This was a retrospective, cross-sectional file review of clozapine-treated patients admitted over the 2-year study period. Data variables included: demographics, clinical information, discharge prescription, clozapine-related side effects and details of clozapine discontinuation, where applicable. RESULTS: A cohort of 33.2% of patients from Tara's biological wards received a trial of clozapine. Participants experienced anti-cholinergic clozapine-related side effects that included weight gain (79.5%), tachycardia (35.2%) and constipation (35.2%). Clozapine was discontinued in 13.7% of participants, and no life-threatening side effects or deaths occurred. Significantly more use of flupenthixol decanoate (64.3% vs. 30.7%; p = 0.0322) and anticholinergics (35.7% vs. 11.4%; p = 0.0474) occurred in the clozapine-discontinued group. Polypharmacy rates were high for psychiatric and non-psychiatric medications. CONCLUSION: One-third of patients received clozapine trials, most of whom continued at discharge. Although side effects occurred frequently, life-threatening side effects did not. Clozapine monitoring protocols, side effect rating scales, pre-emptive management of side effects, lifestyle interventions and clinician education may improve outcomes of clozapine use. The use of plasma clozapine levels may be beneficial. CONTRIBUTION: This study expands our limited knowledge regarding current clozapine prescribing trends in South Africa.

Keywords : clozapine; treatment-resistance; schizophrenia; side effect; treatment discontinuation; polypharmacy; South Africa.

        · text in English     · English ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License